Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 6/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928567 | 0.86 | ESR1 (0.50) | MAPTMEN1KMT2AL3MBTL1ESR1 | |
| SCHEMBL4928618 | 0.84 | MAPT (0.54) | MAPTL3MBTL1ESR1ESR2HSP90AA1 | |
| SCHEMBL4934925 | 0.82 | MAPT (0.41) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL4935041 | 0.81 | MAPT (0.51) | MAPTKMT2AL3MBTL1ESR1ESR2 | |
| SCHEMBL4932865 | 0.74 | MAPT (0.50) | MAPTMEN1KMT2AL3MBTL1ESR1 | |
| SCHEMBL4932005 | 0.73 | ESR1 (0.56) | ESR1ESR2HSP90AA1LMNAGAA | |
| SCHEMBL5992116 | 0.70 | ESR1 (0.59) | MAPTMEN1KMT2AESR1ESR2 | |
| SCHEMBL4933001 | 0.70 | ESR1 (0.52) | ESR1ESR2HSP90AA1HSP90AB1 | |
| SCHEMBL4933040 | 0.68 | ESR1 (0.44) | MAPTKMT2AESR1ESR2HSP90AA1 | |
| SCHEMBL4933035 | 0.68 | ESR1 (0.44) | MAPTKMT2AESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | claimed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| EP-1861381-A1 | NOVEL 3-ARYL-1,2-BENZISOXAZOLE DERIVATIVES, COMPOSTIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006090052-A1 | NOVEL 3-ARYL-1,2-BENZISOXAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | UGT2B7, UGT2B17, CYP4X1 | MAPT 4708/4885MEN1 3102/4885KMT2A 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.